{"id":51732,"date":"2025-12-21T21:14:37","date_gmt":"2025-12-21T13:14:37","guid":{"rendered":"https:\/\/flcube.com\/?p=51732"},"modified":"2025-12-21T21:14:39","modified_gmt":"2025-12-21T13:14:39","slug":"fosun-pharma-partners-with-clavis-bio-in-362-5m-strategic-collaboration","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51732","title":{"rendered":"Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration"},"content":{"rendered":"\n<p><strong>Shanghai Fosun Pharmaceutical (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) announced a strategic collaboration with <strong>Clavis Bio, Inc.<\/strong> to jointly develop innovative therapies based on frontier targets nominated by Clavis Bio. The five\u2011year agreement, backed by <strong>Aditum Bio<\/strong>, enables Fosun to receive up to <strong>USD\u202f362.5\u202fmillion<\/strong> per project plus royalties and equity, while retaining exclusive rights in Greater China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure\">Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Term<\/strong><\/td><td>5\u2011year collaboration (2025\u20112030)<\/td><\/tr><tr><td><strong>Target Selection<\/strong><\/td><td>Up to <strong>4 targets per year<\/strong> for preclinical development<\/td><\/tr><tr><td><strong>Fosun\u2019s Role<\/strong><\/td><td>Joint preclinical development; retains Greater China rights<\/td><\/tr><tr><td><strong>Clavis Bio\u2019s Option<\/strong><\/td><td>Exclusive global rights (ex\u2011Greater China) for each project<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Up to <strong>USD\u202f362.5\u202fM<\/strong> per project (exercise fees, milestones, royalties) plus minority equity stake<\/td><\/tr><tr><td><strong>Parent Entity<\/strong><\/td><td>Clavis Bio is a wholly\u2011owned subsidiary established by Aditum Bio fund<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-territory-amp-rights-allocation\">Territory &amp; Rights Allocation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Territory<\/th><th>Rights Holder<\/th><th>Scope<\/th><\/tr><\/thead><tbody><tr><td><strong>Mainland China, Hong Kong, Macau<\/strong><\/td><td>Fosun Pharma<\/td><td>Exclusive development, manufacturing, commercialization<\/td><\/tr><tr><td><strong>Global (ex\u2011Greater China)<\/strong><\/td><td>Clavis Bio (if option exercised)<\/td><td>Exclusive development, manufacturing, commercialization<\/td><\/tr><tr><td><strong>Equity Component<\/strong><\/td><td>Fosun receives minority stake in new Aditum project company<\/td><td>Zero\u2011cost equity for each exercised project<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Fosun:<\/strong> <strong>$362.5\u202fmillion potential per project<\/strong> monetizes early\u2011stage R&amp;D while retaining <strong>China market exclusivity<\/strong>; diversifies pipeline with frontier targets; aligns with <strong>innovation\u2011driven growth strategy<\/strong>.<\/li>\n\n\n\n<li><strong>For Clavis\/Aditum:<\/strong> <strong>Access to Fosun\u2019s R&amp;D capabilities<\/strong> and China market insights; <strong>flexible option structure<\/strong> de\u2011risks global development; <strong>Aditum\u2019s fund model<\/strong> enables efficient capital allocation across multiple projects.<\/li>\n\n\n\n<li><strong>For Market:<\/strong> Demonstrates <strong>cross\u2011border biotech collaboration model<\/strong>; <strong>frontier target focus<\/strong> positions both parties in <strong>next\u2011generation therapeutics<\/strong> (e.g., novel modalities, undruggable targets); <strong>financial structure<\/strong> sets template for future China\u2011global partnerships.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding project advancement, milestone achievements, and market potential. Actual results may differ due to scientific risks, competitive dynamics, or regulatory changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a strategic collaboration with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51735,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4516,159,893,892],"class_list":["post-51732","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-clavis-bio","tag-fosun-pharmaceutical","tag-hkg-2196","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a strategic collaboration with Clavis Bio, Inc. to jointly develop innovative therapies based on frontier targets nominated by Clavis Bio. The five\u2011year agreement, backed by Aditum Bio, enables Fosun to receive up to USD\u202f362.5\u202fmillion per project plus royalties and equity, while retaining exclusive rights in Greater China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51732\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration\" \/>\n<meta property=\"og:description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a strategic collaboration with Clavis Bio, Inc. to jointly develop innovative therapies based on frontier targets nominated by Clavis Bio. The five\u2011year agreement, backed by Aditum Bio, enables Fosun to receive up to USD\u202f362.5\u202fmillion per project plus royalties and equity, while retaining exclusive rights in Greater China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51732\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-21T13:14:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-21T13:14:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1909.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51732#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51732\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration\",\"datePublished\":\"2025-12-21T13:14:37+00:00\",\"dateModified\":\"2025-12-21T13:14:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51732\"},\"wordCount\":318,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51732#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1909.webp\",\"keywords\":[\"Clavis Bio\",\"Fosun Pharmaceutical\",\"HKG: 2196\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51732#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51732\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51732\",\"name\":\"Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51732#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51732#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1909.webp\",\"datePublished\":\"2025-12-21T13:14:37+00:00\",\"dateModified\":\"2025-12-21T13:14:39+00:00\",\"description\":\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a strategic collaboration with Clavis Bio, Inc. to jointly develop innovative therapies based on frontier targets nominated by Clavis Bio. The five\u2011year agreement, backed by Aditum Bio, enables Fosun to receive up to USD\u202f362.5\u202fmillion per project plus royalties and equity, while retaining exclusive rights in Greater China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51732#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51732\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51732#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1909.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1909.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51732#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a strategic collaboration with Clavis Bio, Inc. to jointly develop innovative therapies based on frontier targets nominated by Clavis Bio. The five\u2011year agreement, backed by Aditum Bio, enables Fosun to receive up to USD\u202f362.5\u202fmillion per project plus royalties and equity, while retaining exclusive rights in Greater China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51732","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration","og_description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a strategic collaboration with Clavis Bio, Inc. to jointly develop innovative therapies based on frontier targets nominated by Clavis Bio. The five\u2011year agreement, backed by Aditum Bio, enables Fosun to receive up to USD\u202f362.5\u202fmillion per project plus royalties and equity, while retaining exclusive rights in Greater China.","og_url":"https:\/\/flcube.com\/?p=51732","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-21T13:14:37+00:00","article_modified_time":"2025-12-21T13:14:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1909.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51732#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51732"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration","datePublished":"2025-12-21T13:14:37+00:00","dateModified":"2025-12-21T13:14:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51732"},"wordCount":318,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51732#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1909.webp","keywords":["Clavis Bio","Fosun Pharmaceutical","HKG: 2196","SHA: 600196"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51732#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51732","url":"https:\/\/flcube.com\/?p=51732","name":"Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51732#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51732#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1909.webp","datePublished":"2025-12-21T13:14:37+00:00","dateModified":"2025-12-21T13:14:39+00:00","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a strategic collaboration with Clavis Bio, Inc. to jointly develop innovative therapies based on frontier targets nominated by Clavis Bio. The five\u2011year agreement, backed by Aditum Bio, enables Fosun to receive up to USD\u202f362.5\u202fmillion per project plus royalties and equity, while retaining exclusive rights in Greater China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51732#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51732"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51732#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1909.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1909.webp","width":1080,"height":608,"caption":"Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51732#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1909.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51732"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51732\/revisions"}],"predecessor-version":[{"id":51736,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51732\/revisions\/51736"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51735"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}